Objective To explore the clinical efficacy and safety of sunitinib combined with multi-target antigen peptide autoimmune cell technology (MASCT) in the treatment of advanced metastatic renal cell carcinoma (RCC).Methods Fifty-two patients with advanced metastatic RCC treated in our hospital between January 2016 and January 2017 were selected in this study. They were divided into the control group and observation group according to different therapies. Patients in the control group (n=22) were treated with MASCT therapy, while those in observation group (n=30) were treated with sunitinib plus MASCT. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of interleukin-17 (IL-17), vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1α (HIF-1α), and platelet-derived growth factor (PDGF) before and after treatment. Calculate the tumor microvessel density (MVD) and compare the clinical efficacy, progression-free survival (PFS), overall survival (OS) and incidence of adverse reactions between the two groups.Results The effective rate of the observation group (86.7%) was significantly higher than that of the control group (59.1%) (P<0.05). After treatment, the serum levels of IL-17, VEGF, HIF-1α and PDGF of patients were significantly reduced in both groups, and the levels of the above indicators were lower in the observation group than in the control group (P<0.05). Moreover, the MVD in both groups decreased significantly, and it was also lower in the observation group than in the control group (P<0.05). Patients in the observation group had significantly longer PFS and OS than those in the control group (P<0.05). No statistical differences were found in the incidence of nausea, vomiting, diarrhea, fatigue, constipation, facial edema, hair loss, hypertension, gray hair, thrombocytopenia, neutropenia, anemia, elevated uric acid, hypothyroidism, elevated alanine aminotransferase, oral mucositis, skin discoloration, icteric skin, hand and foot syndrome and other adverse reactions between the observation group and control group (P>0.05).Conclusion Sunitinib combined with MASCT could improve the clinical curative effect, reduce the serum levels of related tumor markers, and prolong the PFS and OS of advanced metastatic RCC patients, with no increase of adverse reactions, so it is worth of clinical promotion.